Genmab — December 2017

bibob

Så kan de jo bare se at rubbe sig. Vi har ikke tid til alt det pjat.

E_L

tweet on AL amyloidosis https://twitter.com/BursatilBiotech/status/943903615126851586

E_L

Highlights from ASH 2017: Research Update on AL amyloidosis http://www.arci.org/blog-1/2017/12/14/highlights-from-ash-2017-research-update

E_L

video - Major breakthroughs in AL amyloidosis treatment from ASH 2017 - https://www.vjhemonc.com/video/fpeohrztdaq-major-breakthroughs-in-al-amyloidosis-treatment-from-ash-2017/

bibob

Thanks E L. Again we see that Dara is a unik drug. So,- go on, use it.

Helge_LarsenPI-redaktør

Et lille sidespring. Hermed min analyse fra i dag på Nuevolution lægemiddeludviklingsmaskine. http://www.proinvestor.com/aktieanalyser/255/

E_L

Helge giving us some Xmas reading; he is worried we will be bored!

JKY_VH

Tak E L

E_L

Did we see this before? :

E_L

Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. - https://www.ncbi.nlm.nih.gov/pubmed/29260507

E_L

i mean , it is a small study, but ORR = 100%

E_L

One hundred percent.

E_L

all of them.

nohope

Helge´s Christmas Fairy Tales are great ! I fell asleep halfway through. Will spare other half for next time I can´t sleep.

pauly

very impresive EL

Thestrup7

Har https://finance.yahoo.com/news/brief-janssen-enters-collaboration-license-223259225.html

Thestrup7

Nogen betydning for Genmab?

Sukkeralf

Endnu en bekræftigelse på at CAR-T BCMA skal tages alvorligt - dog bedre at Janssen får kontrol med Legens behandling og ikke en anden stor konkurrent. Så må vi se hen ad vejen om der bliver kombineret med Daratumumab på en eller anden måde

Sukkeralf

Legends behandling fyldte ikke meget på ASH, men

Sukkeralf

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric...

BioCentury (www.biocentury.com)